Efficacy of topical agents in oral mucositis prevention: Systematic review and network meta‐analysis

Abstract Background Oral mucositis (OM) is considered one of the most common side effects of patients undergoing cancer therapy. OM prevention plays a crucial role in the effectiveness of cancer treatment and the patient's quality of life. Different preventive treatments have been proposed in c...

Full description

Saved in:
Bibliographic Details
Published in:Oral diseases 2024-06
Main Authors: Coppini, Martina, Caponio, Vito Carlo Alberto, Mauceri, Rodolfo, Bizzoca, Maria Eleonora, Laino, Luigi, Lorenzo‐Pouso, Alejandro I., Russo, Diana, Troiano, Giuseppe, Silva, Fábio França Vieira E., Lo Muzio, Lorenzo, Campisi, Giuseppina
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Oral mucositis (OM) is considered one of the most common side effects of patients undergoing cancer therapy. OM prevention plays a crucial role in the effectiveness of cancer treatment and the patient's quality of life. Different preventive treatments have been proposed in clinical trials, however with inconclusive results. Materials and Methods A systematic review search was conducted in PubMed, Scopus, Web of Science, and Cochrane Database to answer the PICO question: in cancer patients, do specific topical agents compared to standard treatments or placebo reduce the onset and severity of oral mucositis? The risk of bias was assessed, and a network meta‐analysis was conducted. Results Of 2913 results, 30 randomized clinical trials were considered suitable for inclusion. A total of 2564 patients were analyzed, of which 1284 belonged to the test group and 1280 belonged to the control group. Natural products were the most used, followed mainly by antimicrobial agents, coating agents, and basic oral care measures. Topical sucralfate resulted in the most powerful intervention for the OM prevention (OR = 0.04, 95%C.I. = 0.01–0.25, p ‐value = 0.001). Conclusion Due to its cytoprotective action, low cost, ease of administration, and safety, sucralfate could become a potential ally to prevent the onset of OM during cancer therapy.
ISSN:1354-523X
1601-0825
1601-0825
DOI:10.1111/odi.15046